Related Experiment Video

Updated: Feb 15, 2026

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity
09:52

Trans-Tympanic Drug Delivery for the Treatment of Ototoxicity

Published on: March 16, 2018

10.0K

Cancer Treatment with Liposomes Based Drugs and Genes Co-delivery Systems

Chuanmin Zhang1,2, Shubiao Zhang2, Defu Zhi2

  • 1State Key Laboratory of Fine Chemicals, Dalian University of Technology, Dalian 116024, China.

Current Medicinal Chemistry
|January 16, 2018
PubMed

Insights

Liposomes-based co-delivery systems can overcome cancer drug resistance by simultaneously delivering drugs and genes. This synergistic approach enhances cancer cell death and improves therapeutic outcomes.

Area of Science:

  • Biomedical Engineering
  • Nanotechnology
  • Cancer Therapy

Background:

  • Cancer cells develop resistance to treatments through mechanisms like increased anti-apoptosis, drug efflux, angiogenesis, DNA repair, and altered cell cycle checkpoints.
  • These resistance mechanisms limit the curative effects of conventional anticancer drugs.
  • Liposomes-based co-delivery systems offer a promising strategy to overcome cancer resistance.

Purpose of the Study:

  • To review liposomes-based co-delivery systems for overcoming cancer resistance.
  • To discuss the synergistic effects of combined anticancer drugs and genes delivered via liposomes.
  • To provide insights into the challenges and future development of these systems in cancer therapy.

Main Methods:

  • Review of existing literature on liposomes-based co-delivery systems in cancer therapy.
  • Analysis of studies demonstrating synergistic anti-cancer effects of drugs and genes co-delivered by liposomes.
  • Discussion of various cancer models utilizing multifunctional liposomes for co-delivery.

Main Results:

  • Liposomes-based co-delivery systems can simultaneously target multiple resistance pathways in cancer cells.
  • Co-delivery of drugs and genes exhibits synergistic anti-cancer effects, enhancing cancer cell death.
  • These systems show potential in sensitizing resistant cancer cells to death stimuli.

Conclusions:

  • Liposomes-based co-delivery systems represent a viable strategy to combat cancer drug resistance.
  • The synergistic action of co-delivered drugs and genes is key to overcoming resistance mechanisms.
  • Further research and development are needed to address challenges and optimize these systems for clinical application.
Keywords:
Co-deliverycancer therapydruggeneliposomessynergistic effects.

More Related Videos

Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy07:12

Spatio-Temporal In Vivo Imaging of Ocular Drug Delivery Systems using Fiberoptic Confocal Laser Microendoscopy

Published on: September 27, 2021

2.8K
Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes10:33

Delivery of Therapeutic siRNA to the CNS Using Cationic and Anionic Liposomes

Published on: July 23, 2016

11.2K

Related Concept Videos

Transdermal Drug Delivery Systems01:18

Transdermal Drug Delivery Systems

Transdermal drug delivery systems (TDDS) enable the controlled release of drugs across the skin into systemic circulation. They are particularly advantageous for drugs with short half-lives or narrow therapeutic indices, as they maintain consistent plasma concentrations and reduce the risk of subtherapeutic or toxic levels.TDDS are categorized into monolithic, reservoir, and mixed systems. Monolithic systems embed the drug in a polymer matrix, where diffusion governs release. Reservoir systems...
23
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
22
Intrauterine Drug Delivery Systems01:21

Intrauterine Drug Delivery Systems

Controlled-release systems for intravaginal and intrauterine drug delivery have been developed primarily for the administration of contraceptive steroid hormones. These delivery routes circumvent first-pass hepatic metabolism, thereby enhancing bioavailability and allowing for reduced systemic dosages compared to oral administration. Such approaches contribute to improved therapeutic efficacy and patient compliance, particularly in long-term contraceptive regimens.Intravaginal Drug Delivery...
20
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
16
Oral Drug Delivery Systems: Continuous-Release Systems01:26

Oral Drug Delivery Systems: Continuous-Release Systems

Continuous-release drug delivery systems offer a strategic approach to maintaining therapeutic drug levels over extended periods following oral administration. By modulating the release rate of active pharmaceutical ingredients, these systems minimize fluctuations in plasma concentrations, which enhances clinical efficacy and reduces the need for frequent dosing. Such characteristics make them particularly advantageous in managing chronic diseases where patient adherence and stable drug...
20
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
24